medigraphic.com
ISSN 1561-3127 (Electronic)
ISSN 0864-3466 (Print)

2020, Number 1

<< Back Next >>

Revista Cubana de Salud Pública 2020; 46 (1)

Lipid disorders in Hispanic Americans patients in the primary health care level in Lima, Peru

Moya-Salazar J, Pio-Dávila L

Language: Spanish
References: 35
Page: 1-22
PDF size: 531.17 Kb.


ABSTRACT

Introduction: Dyslipidemia is a risk factor for the development of cardiovascular diseases, which are considered to be the main cause of death at the global level.
Objectives: To assess lipid disorders in Hispanic Americans patients in the primary health care level in Lima.
Methods: In the period 2015-2016 a prospective research was made in 117 patients of the Service of Clinical Laboratory, La Fe Policlinic in Lima. There were used the guides named National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III), US Preventive Services Task Force, and the clinical practice guidelines of the Mexican Institute of Social Security. The lipid variables were established in accordance with each guide: High Triglycerides (TG) (TG ≥150 mg/dl) and high total cholesterol (CT ≥ 200 mg/dl), High LDLC cholesterol (LDL-C ≥ 130 mg/dl) and decreased HDL-C (HDL-C ≤ 40 mg/dl).
Results: 71 % of the patients presented decreased HDL-C, 41 % hypertriacilglyceridemia, 35.9 % hypercholesterolemia and 33.3 % high LDL-C. According to the US Preventive Services Task Force guide 9 patients with dyslipidemia grade B were identified by the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guide, and 99 patients in 4 groups of dyslipidemia and 5 patients without lipid disorders were identified according to the clinical practice guidelines of the Mexican Institute of Social Security.
Conclusions: It is observed a high frequency of patients with lipid disorders mainly by decreased HDL-C and there is evidence of the advantages of the clinical practice guidelines in the primary level of health care.


REFERENCES

  1. Furgione A, Sánchez D, Scott G, Luti Y, Arraiz N, Bermúdez V, et al. Dislipidemias primarias como factor de riesgo para la enfermedad coronaria. Rev Latinoam Hipertensión. 2009;4(1):18-25.

  2. Pickels EG. The ultracentrifuge: practical aspects of the ultracentrifugal analysis of proteins. Chem Rev. 1942;30:341-55.

  3. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins an integrated approach to mechanisms and disorders. N Engl J Med. 1967;276:34-42.

  4. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of lowdensity lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.

  5. Center for Disease Control and Prevention. Heart Disease Facts. Heart Disease Statistics and Maps. Atlanta, Georgia, November 28; 2017 [acceso 20/06/17]. Disponible en: https://www.cdc.gov/heartdisease/facts.htm

  6. Mensah GA, Brown DW. An overview of cardiovascular disease burden in the United States. Health Aff (Millwood). 2007;26(1):38-48.

  7. Levenson JW, Skerrett PJ, Gaziano JM. Reducing the global burden of cardiovascular disease: the role of risk factors. P Rev Cardiol. 2002;5:188-99.

  8. Núñez M, Rojas J, Torres W, González R, Mejías JC, Olivar LC, et al. Características sociodemográficas asociadas a dislipidemia en el estudio de prevalencia de síndrome metabólico de Maracaibo, Venezuela. Rev Latinoam Hipertensión. 2013;8(4):77.

  9. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-89.

  10. Brown CD, Higgins M, Donato KA, Rohde FC, Garrison R, Obarzanek E, et al. Body mass index and the prevalence of hypertension and dyslipidemia. Obesity Res. 2000;8:600-19.

  11. Onat A, Hergenc G, Sari I, Türkmen S, Can G, Sansoy V. Dyslipidemia hypertension: distinctive features and cardiovascular risk in a prospective population-based study. Am J Hypertension. 2005;18:409-16.

  12. Ponte-Negretti CI, Isea-Pérez J, Lanas F, Medina J, Gomez-Mancebo J, Morales E, et al. Atherogenic Dyslipidemia in Latin America: Prevalence, causes and treatment: Expert's position paper made by The Latin American Academy for the Study of Lipids (ALALIP) Endorsed by the Inter-American Society of Cardiology (IASC), the South American Society of Cardiology (SSC), the Pan-American College of Endothelium (PACE), and the International Atherosclerosis Society (IAS). Int J Cardiol. 2017;243:516-22. DOI: 10.1016/j.ijcard.2017.05.059

  13. Lazo-Porras M, Bernabe-Ortiz A, Malaga G, Gilman RH, Acuna-Villaorduña A, Cardenas-Montero D, et al. Low HDL cholesterol as a cardiovascular risk factor in rural, urban, and rural-urban migrants: PERU MIGRANT cohort study. Atherosclerosis. 2016;246:36-43. DOI: 10.1016/j.ijcard.2015.12.039

  14. Tóth PP, Potter D, Ming EE. Prevalence of lipid abnormalities in the United States: The National Health and Nutrition Examination Survey 2003–2006. J Clin Lipidol. 2012;6:325-30.

  15. CLSI H18-A4. Procedures for the Handling and Processing of Blood Specimens for Common. Laboratory Tests; Approved Guideline-Fourth Edition. CLSI document H18- A4. Clinical and Laboratory Standard Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA; 2007.

  16. Nikolac N, Šupak-Smolčić V, Šimundić A, Ćelap I. Croatian Society of Medical Biochemistry and Laboratory Medicine: national recommendations for venous blood sampling. Biochem Med (Zagreb). 2013;23(3):242-254.

  17. Moya-Salazar J, Pio-Davila L. Evaluation of inter-batch variability in establishing and quality control of glucose. Med Univ. 2016;18(71):85-90.

  18. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation. 2002;106:3143-421.

  19. U.S. Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr, et al. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults, US Preventive Services Task Force Recommendation Statement. JAMA. 2016; 316(19):1997-2007. DOI:10.1001/jama.2016.15450

  20. Canalizo-Miranda E, Favela-Pérez EA, Salas-Anaya JA, Gómez-Díaz R, Jara-Espino R, Torres-Arreola L, et al. Clinical practice guidelines. Diagnosis and treatment of dyslipidemia. Rev Med Inst Mex Seguro Soc. 2013;51(6):700-9.

  21. American Diabetes Association. Classification and Diagnosis of Diabetes. Diabetes Care. 2017;40(Suppl. 1):S11–S24. DOI: 10.2337/dc17-S005

  22. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: Findings from the third national health and nutrition examination survey, 1988-1994. Arch Pediatr Adolesc Med. 2003;157(8):821-7. DOI: 10.1001/archpedi.157.8.821

  23. Medina-Lezama J, Zea-Diaz H, Morey-Vargas OL, Bolaños-Salazar JF, Muñoz- Atahualpa E, Postigo-MacDowall M, et al. Prevalence of the metabolic syndrome in Peruvian Andean hispanics: The PREVENCION study. Diabetes Res Clin Pract. 2007; 78(2):270-81. DOI: 10.1016/j.diabres.2007.04.004

  24. Vinueza R, Boissonnet CP, Acevedo M, Uriza F, Benitez FJ, Silva H, et al. Dyslipidemia in seven Latin American cities: CARMELA study. Preventive Medicine 2010;50:106- 111.

  25. Núñez-Robles E, Huapaya-Pizarro C, Torres-Lao R, Esquivel-León S, Suarez-Moreno V, Yasuda-Espinoza M. Prevalencia de factores de riesgo cardiovascular y riesgo metabólico en escolares, universitarios y mujeres de organizaciones sociales de base en distritos de Lima, Callao, La Libertad y Arequipa, Perú 2011. Rev Perú Med Exp Salud Publica. 2014;31(4):652-59.

  26. Márquez-Sandoval F, Macedo-Ojeda G, Viramontes-Hörner D, Fernández Ballart J, Salas Salvadó J, Vizmanos B. The prevalence of metabolic syndrome in Latin America: a systematic review. Public Health Nutr. 2011;14(10):1702-13. DOI: 10.1017/S1368980010003320

  27. García F, Solís J, Calderón J, Luque E, Neyra L, Manrique H, et al. Prevalencia de diabetes mellitus y factores de riesgo relacionados en una población urbana. Rev Soc Peru Med Interna. 2007;20(3):90-94.

  28. Scheidt-Nave C, Du Y, Knopf H, Schienkiewitz A, Ziese T, Nowossadeck E, et al. Verbreitung von Fettstoffwechselstörungen bei Erwachsenen in Deutschland. Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). Bundesgesundheitsbl 2013;56:661-667. DOI 10.1007/s00103-013-1670-0

  29. Beltrán-Sánchez H, Harhay MO, Harhay MM, McElligott S. Prevalence and Trends of Metabolic Syndrome in the Adult U.S. Population, 1999-2010. J Am Coll Cardiol. 2013;62(8):697-703. DOI: 10.1016/j.jacc.2013.0 5.064

  30. Martínez-Hernández A, Chávez-Aguirre R. Prevalencia y comorbilidad de dislipidemias en el primer nivel de atención. Rev Med Inst Mex Seguro Soc. 2007;45(5):469-475.

  31. Delisle H, Desilets MC, Vargas ER, Garrel D. Metabolic syndrome in three ethnic groups using current definitions. Appl. physiology, Nutr. metabolism Physiologie appliquee, Nutr. metabolisme. 2008;33(2):356-360.

  32. Málaga G, Zevallos-Palacios C, Lazo M, Huayanay C. elevada frecuencia de dislipidemia y glucemia basal alterada en una población peruana de altura. Rev Peru Med Exp Salud Publica. 2010;27(4):557-61.

  33. Schuster H. The GALAXY Program: An Update on Studies Investigating Efficacy and Tolerability of Rosuvastatin for Reducing Cardiovascular Risk. Expert Rev Cardiovasc Ther. 2007;5(2):177-93.

  34. Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias. European Heart J. 2011;32:1769-1818. DOI:10.1093/eurheartj/ehr158

  35. Frieden TR, Berwick DM. The "Million Hearts" initiative–preventing heart attacks and strokes. N Engl J Med. 2011;365:e27.




2020     |     www.medigraphic.com